Direct-to-consumer telehealth platform delivering treatments for weight loss, men's health, dermatology, and fertility.
Ro is a direct-to-consumer telehealth platform that diagnoses patients, prescribes treatments, and delivers medication, with a particularly strong franchise in men's health (Roman), weight loss (compounded GLP-1s and Plenity), and fertility (Modern Fertility). Sacra estimates 2024 revenue at $598M (+66% YoY), and the company has held a $7B valuation since its 2022 Series D — well off its 2021 peak — with renewed IPO chatter as GLP-1 demand explodes.
Healthcare📍 New York, NYFounded 2017
Current Valuation
$7.0B
as of 2025
UNICORN
QL Price
$7.0B
0% vs last round
QuantLogix's current estimate for Ro, published 2026-10-07 — in line with the last disclosed round of $7.0B (2025).
Confidence
low
Basis
round anchored
What backs this price
Last disclosed round
$7.0B
2025
weight 0.59
How this price has held up
No round has priced for Ro since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-10-07 and will be graded against the next priced round. See the full accuracy record →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, Ro, 2026-10-07 (8cb157642a08c270).
The id pins this exact claim, so a citation stays checkable after the price moves.
Model estimate for research — not a quote, target price, or investment advice.
IPO Outlookrumored
Is Ro going public in 2026?
An IPO is rumored for 2026, with nothing filed. Ro remains private and the date is not the company's.
What is Ro's valuation in 2026?
Ro is valued at $7.0B as of 2025, set by its Series D ($150M, Feb 2022). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has Ro filed an S-1?
No public S-1 is on file for Ro as of 10/07/2026; the IPO is rumored.
Who are Ro's investors?
Ro's investors include General Catalyst, FirstMark Capital, ShawSpring Partners, Tiger Global, TQ Ventures, BoxGroup.
How much has Ro raised?
Ro has raised $1.0B in total, most recently a Series D of $150M in Feb 2022.
Is Ro publicly traded — can you buy Ro stock?
No. Ro is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for Ro on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
CEO
Zachariah Reitano
Founded
2017
HQ
New York, NY
Employees
~1000
Total Raised
$1.0B
Est. Revenue
$598M (2024)
Growth
+66% YoY
Last Round
Series D — $150M (Feb 2022) · Lead: General Catalyst
IPO Status
rumored
Fundraising Status
Series D · $150M · 4y 8mo ago
rumoredTotal raised $1.0B
Latest Funding Round
Round
Amount
Date
Lead Investor
Post-Money
Series D
$150M
Feb 2022
General Catalyst
—
Talent Signal
Hiring trend
▶ Hiring steady
-6% vs 2026-08
Open roles
48
via lever
Product-build share
69%
engineering, research, product, design
Trajectory
steady
heavy product build — 69% of open roles are product-building functions (engineering/research/product) — 18 of 48 open roles are medical.
Actively hiring with no tracked executive churn.
Open roles by month
Open roles by function
■ product-building ■ go-to-market / G&A
Compounding Pharmacy Technician - Romeoville, ILCompounding Pharmacy Technician - Boynton Beach, FLCompounding Pharmacy Technician - Boynton Beach, FL (Temp)Director, Pharmacy AutomationEngineering Manager, Core InfrastructureFulfillment Pharmacist - Boynton Beach, FL
Counted from Ro's live job board as of 2026-09-15; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
Founders & Key People
Zachariah ReitanoSaman RahmanianRob Schutz
Investors
General Catalyst · FirstMark Capital · ShawSpring Partners · Tiger Global · TQ Ventures · BoxGroup
Products
Roman (men's health & ED)
Ro Body (GLP-1 weight loss)
Plenity
Modern Fertility
Ro Pharmacy
Workpath at-home diagnostics
Competitors
Hims & Hers · Noom · Teladoc · Lemonaid Health · Form Health
telehealthGLP-1weight-lossDTCpharmacy
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2025. Refreshed quarterly.